Walter S. Woltosz, a director and 10% owner of Simulations Plus, Inc. (NASDAQ:SLP), along with Virginia E. Woltosz, also a 10% owner, executed a sale of 4,177 shares of the company’s common stock on July 1, 2026. The transactions, valued at $77,023, were conducted at prices between $18.36 and $18.49 per share. The sale followed a Rule 10b5-1 trading plan adopted by the reporting persons. Post-transaction, the Woltoszes hold 3,202,131 shares directly, a figure reflecting a correction to prior disclosures. Simulations Plus trades at $18.36 with a $371 million market cap. InvestingPro analysis suggests the stock is undervalued based on fair value metrics, and the company holds a "GOOD" financial health score with more cash than debt. Additionally, Simulations Plus has agreed to an acquisition by affiliates of Altaris, LLC in an all-cash transaction valued at $18.50 per share, representing a 26% premium to the company’s 60-day volume-weighted average price as of mid-June 2026. Following this announcement, William Blair downgraded Simulations Plus stock to Market Perform from Outperform. Meanwhile, Simulations Plus is enhancing its AI platform for drug development by collaborating with Nvidia, utilizing the BioNeMo Agent Toolkit. This initiative builds on previous work to integrate GPU-accelerated computing and AI capabilities into drug development modeling workflows. Citizens has reiterated a Market Outperform rating for NRC Health, maintaining a price target of $23.00. These developments reflect the companies’ ongoing strategic initiatives and market evaluations.
Key Points
- Walter and Virginia Woltosz sold 4,177 shares via a Rule 10b5-1 plan, reducing their direct holdings to 3,202,131 shares.
- Simulations Plus is targeted for acquisition at $18.50 per share, a 26% premium, while facing an analyst downgrade from William Blair.
- The company is expanding its AI capabilities through a partnership with Nvidia, focusing on GPU-accelerated drug development modeling.
Risks and Uncertainties
- The acquisition by Altaris, LLC affiliates introduces execution risk and potential integration challenges for Simulations Plus.
- The downgrade from William Blair to Market Perform may impact investor sentiment and stock volatility in the life sciences technology sector.
- Reliance on AI and GPU-accelerated computing partnerships may face technological adoption hurdles in the pharmaceutical development market.